Creating a New Way Forward

Working closely with leading cancer centers, community oncology clinics, and teams of patients, Blue Note is developing clinically validated prescription digital therapeutics to help reduce anxiety, depression, and other distress related to cancer.


Geoff Eich


Rick Lit

Scientific Operations

Michael McKinley

Product Development

Michael Malecki

Access & Reimbursement

Mark Elfers

Finance & Operations

Laura Chavaree

Patient Engagement

Dianne Shumay, PhD

Clinical Psycho Oncology

Jen Feng

Senior Product Manager

Board of Directors

Andrew Firlik, MD

Jazz Venture Partners

John Harris

Jazz Venture Partners

Geoff Eich

Blue Note Therapeutics

Board of Advisors

Michael Antoni, PhD

Sylvester Comprehensive Cancer Center

Bio  Research

Patricia Ganz, MD

UCLA Jonsson Comprehensive Cancer Center

Bio  Research

Lidia Schapira, MD

Stanford University Medical Center

Bio  Research

Marcus Neubauer, MD

The US Oncology Network

Bio  Research

Our Pipeline

Blue Note's products will serve all cancer patients, from early stage through survivorship, in both the in-patient and out-patient settings.

Product Candidate Disease Progression Development Proof of Concept Pivotal Trial FDA Review
BNT001 Early - Mid Stage  
BNT201 Acute In-patient    
BNT301 Late Stage      
BNT401 Survivorship      
Product Candidate Disease Progression Status
BNT001 Early - Mid Stage 2
BNT201 Acute In-patient 1
BNT301 Late Stage 0
BNT401 Survivorship 0
0 = Development
1 = Proof of Concept
2 = Pivotal Trial
3 = FDA Review

We Can't Do This Alone

Blue Note Therapeutics is honored to work with the National Comprehensive Cancer Network (NCCN) and other leading cancer care organizations in our quest to help cancer patients live better.